NASDAQ:TSBX Turnstone Biologics (TSBX) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free TSBX Stock Alerts $2.66 -0.07 (-2.56%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$2.61▼$2.7950-Day Range$2.60▼$3.6652-Week Range$1.63▼$13.20Volume109,567 shsAverage Volume142,738 shsMarket Capitalization$61.53 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Turnstone Biologics alerts: Email Address Turnstone Biologics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside614.3% Upside$19.00 Price TargetShort InterestBearish5.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.78Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.34) to ($3.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.09 out of 5 starsMedical Sector586th out of 914 stocksBiological Products, Except Diagnostic Industry95th out of 153 stocks 3.3 Analyst's Opinion Consensus RatingTurnstone Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageTurnstone Biologics has received no research coverage in the past 90 days.Read more about Turnstone Biologics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.22% of the float of Turnstone Biologics has been sold short.Short Interest Ratio / Days to CoverTurnstone Biologics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Turnstone Biologics has recently increased by 9.65%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTurnstone Biologics does not currently pay a dividend.Dividend GrowthTurnstone Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TSBX. Previous Next 1.2 News and Social Media Coverage News SentimentTurnstone Biologics has a news sentiment score of -0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Turnstone Biologics this week, compared to 0 articles on an average week.Search Interest4 people have searched for TSBX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Turnstone Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Turnstone Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders32.10% of the stock of Turnstone Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.51% of the stock of Turnstone Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Turnstone Biologics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Turnstone Biologics are expected to grow in the coming year, from ($3.34) to ($3.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Turnstone Biologics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Turnstone Biologics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTurnstone Biologics has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Turnstone Biologics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About Turnstone Biologics Stock (NASDAQ:TSBX)Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.Read More TSBX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TSBX Stock News HeadlinesMay 16 at 11:03 AM | markets.businessinsider.comLeerink Partners Reaffirms Their Hold Rating on Turnstone Biologics Corp. (TSBX)May 13, 2024 | investorplace.comTSBX Stock Earnings: Turnstone Biologics Misses EPS for Q1 2024May 13, 2024 | globenewswire.comTurnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business HighlightsMay 11, 2024 | finance.yahoo.comTurnstone Biologics Corp. (TSBX)May 8, 2024 | globenewswire.comTurnstone Biologics to Present at the 2024 Bank of America Securities Health Care ConferenceApril 18, 2024 | uk.investing.comTurnstone Biologics announces board member resignationApril 16, 2024 | globenewswire.comTurnstone Biologics Appoints William Waddill to its Board of DirectorsApril 12, 2024 | seekingalpha.comTSBX Turnstone Biologics Corp.March 22, 2024 | investorplace.comTSBX Stock Earnings: Turnstone Biologics Beats EPS for Q4 2023March 21, 2024 | globenewswire.comTurnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business HighlightsMarch 2, 2024 | finance.yahoo.comTurnstone Biologics Corp. (NASDAQ:TSBX) institutional investors have had a good week as stock gains 34%February 23, 2024 | benzinga.comTurnstone Biologics Stock (NASDAQ:TSBX), Short Interest ReportFebruary 21, 2024 | finance.yahoo.comTurnstone Biologics to Participate in Upcoming Investor ConferencesFebruary 21, 2024 | globenewswire.comTurnstone Biologics to Participate in Upcoming Investor ConferencesFebruary 20, 2024 | finance.yahoo.comTurnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.February 20, 2024 | globenewswire.comTurnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.January 23, 2024 | msn.comRUM, ENVB and GAME among mid-day moversJanuary 21, 2024 | finance.yahoo.comHere's Why Turnstone Biologics (NASDAQ:TSBX) Must Use Its Cash WiselyJanuary 3, 2024 | seekingalpha.comIPOs In 2023 Disappoint But 2024 Looks BrighterNovember 27, 2023 | finance.yahoo.comTurnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare ConferenceNovember 19, 2023 | realmoney.thestreet.comTurnstone Biologics price target lowered to $15 from $18 at BofANovember 10, 2023 | msn.comTurnstone Biologics GAAP EPS of -$1.00November 10, 2023 | msn.comTurnstone Biologics GAAP EPS of $1.00November 9, 2023 | finance.yahoo.comTurnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business HighlightsNovember 5, 2023 | morningstar.comTurnstone Biologics Corp TSBXSee More Headlines Receive TSBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Turnstone Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/19/2024Next Earnings (Estimated)9/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TSBX CUSIPN/A CIK1764974 Webturnstonebio.com Phone347-897-5988FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$20.00 Low Stock Price Target$18.00 Potential Upside/Downside+614.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($10.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,200,000.00 Net MarginsN/A Pretax Margin-287.40% Return on Equity-174.96% Return on Assets-72.80% Debt Debt-to-Equity RatioN/A Current Ratio6.72 Quick Ratio8.57 Sales & Book Value Annual Sales$19.31 million Price / Sales3.19 Cash FlowN/A Price / Cash FlowN/A Book Value$3.46 per share Price / Book0.77Miscellaneous Outstanding Shares23,130,000Free Float15,704,000Market Cap$61.53 million OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Sammy J. Farah M.B.A. (Age 52)Ph.D., President, CEO & Director Comp: $678.51kDr. Venkat Ramanan Ph.D. (Age 55)Chief Financial Officer Comp: $346.13kDr. Michael F. Burgess M.D. (Age 60)MBChB, Ph.D., Interim Chief Medical Officer & Executive Director Comp: $212.69kMs. Saryah Azmat (Age 35)Chief Business Officer Comp: $479.73kDr. Vijay Chiruvolu M.B.A. (Age 62)Ph.D., Interim Chief Technology Officer Dr. Stewart Abbot Ph.D. (Age 57)Chief Scientific Officer More ExecutivesKey CompetitorsAVROBIONASDAQ:AVROIkena OncologyNASDAQ:IKNALENZ TherapeuticsNASDAQ:LENZEntera BioNASDAQ:ENTXGenenta ScienceNASDAQ:GNTAView All CompetitorsInsiders & InstitutionsZimmer Partners LPBought 130,826 shares on 5/17/2024Ownership: 0.774%Kathleen S. Wright Associates Inc.Bought 42,553 shares on 4/17/2024Ownership: 0.184%Versant Ventures V, LlcBought 225,000 shares on 7/25/2023Total: $2.70 M ($12.00/share)Rishi GuptaBought 416,666 shares on 7/20/2023Total: $5.00 M ($12.00/share)View All Insider TransactionsView All Institutional Transactions TSBX Stock Analysis - Frequently Asked Questions Should I buy or sell Turnstone Biologics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turnstone Biologics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TSBX shares. View TSBX analyst ratings or view top-rated stocks. What is Turnstone Biologics' stock price target for 2024? 4 Wall Street research analysts have issued twelve-month price targets for Turnstone Biologics' stock. Their TSBX share price targets range from $18.00 to $20.00. On average, they anticipate the company's share price to reach $19.00 in the next year. This suggests a possible upside of 614.3% from the stock's current price. View analysts price targets for TSBX or view top-rated stocks among Wall Street analysts. How have TSBX shares performed in 2024? Turnstone Biologics' stock was trading at $2.55 at the beginning of 2024. Since then, TSBX stock has increased by 4.3% and is now trading at $2.66. View the best growth stocks for 2024 here. When is Turnstone Biologics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, September 6th 2024. View our TSBX earnings forecast. How were Turnstone Biologics' earnings last quarter? Turnstone Biologics Corp. (NASDAQ:TSBX) issued its earnings results on Thursday, March, 21st. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.13. When did Turnstone Biologics IPO? Turnstone Biologics (TSBX) raised $80 million in an IPO on Friday, July 21st 2023. The company issued 6,666,667 shares at $12.00 per share. Who are Turnstone Biologics' major shareholders? Turnstone Biologics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Zimmer Partners LP (0.77%) and Kathleen S. Wright Associates Inc. (0.18%). Insiders that own company stock include Rishi Gupta and Versant Ventures V, Llc. View institutional ownership trends. How do I buy shares of Turnstone Biologics? Shares of TSBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TSBX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressMost important medical advance in 100 yearsThe Oxford ClubUrgent Nvidia WarningAltimetryShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingNext President (Not Trump. Not Biden.)The Freeport Society41 banks launch ‘crypto dollar’Stansberry ResearchWhat’s Really Next for America…Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turnstone Biologics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
